Release Date: 2024-05-28

Association of Infections with Alzheimer’s Disease

Huseyin Yilmaz (Author)

Release Date: 2024-05-28

Oskar Fischer and Alois Alzheimer first suggested a possible link to infections in 1907. Various infectious agents, including viruses, bacteria, spirochetes, fungi, and prions, have been implicated in its etiology. However, the role of these pathogens in AD is complex and intertwined with numerous other factors. Infections may contribute to AD through several mechanisms. When [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inAlzheimer’s Disease From Molecular Mechanisms to Clinical Practices
First Page299
Last Page328
DOIhttps://doi.org/10.69860/nobel.9786053359166.13
ISBN978-605-335-916-6 (PDF)
LanguageENG
Page Count30
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Oskar Fischer and Alois Alzheimer first suggested a possible link to infections in 1907. Various infectious agents, including viruses, bacteria, spirochetes, fungi, and prions, have been implicated in its etiology. However, the role of these pathogens in AD is complex and intertwined with numerous other factors.
Infections may contribute to AD through several mechanisms. When an infectious agent invades the body, the host’s immune response produces a range of chemicals and proteins that can impact the brain. Additionally, the stress response, environmental factors, and treatments can all interact with infectious agents to influence disease progression. Several pathogens have been specifically studied for their potential role in AD. Fungal infections have also been proposed as a contributing factor. Despite these findings, establishing a clear causative role for infections in AD remains challenging. The interactions between infections and other risk factors highlight the complexity of AD etiology, underscoring the need for comprehensive approaches in both research and treatment to address this debilitating condition. This section discusses the role of infectious agents in the pathogenesis of Alzheimer’s disease.

Huseyin Yilmaz (Author)
Professor, Istanbul Cerrahpasa University
https://orcid.org/0000-0002-7897-2358
3Huseyin Yilmaz , Prof.Dr. Professor Huseyin Yilmaz is the group leader and founder of the Department of Virology, Veterinary Faculty of Istanbul University-Cerrahpasa. He has graduated from the Veterinary Faculty of Istanbul University in 1984. He was awarded with PhD in immunology from the Veterinary School at University of Bristol, UK, in 1993. Professor Huseyin led a number of research projects and established research infrastructure to improve detection, epidemiology and prevention of major viral diseases and emerging viral infections affecting animals and humans. He established national and international collaboration with Turkish and European Union institutions through COST actions. Recently, he also established a bilateral research link between The Pirbright Institute and Kansas State University with Department of Virology, funded by the British Council concerning the viral livestock diseases in cattle and poultry. After recent outbreaks of lumpy skin disease in Turkey, he is also working on detection and prevention of transboundary emerging infections like LSD and is collaborating wth the researchers in the Pirbright Institute, UK. International projects were funded by EU (DEFEND project on LSD), Royal Scociety and the British Council. Recently he is involved in influenza D virus project (EU-ICRAD) as well as development of diagnostric kits for Epstein-Barr Virus and Cytomegalovirus infections in humans supported by TUBITAK.

  • Uwishema O, Eneh SC, El Jurdi E, Olanrewaju OF, Abbass Z, Jolayemi MM, et al.Poliovirus returns to the UK after nearly 40 years: current efforts and future recommendations. Postgrad Med J. 2022;98(1165):816-819.

  • Catumbela CSG, Giridharan VV, Barichello T, Morales R. Clinical evidence of human pathogens implicated in Alzheimer's disease pathology and the therapeutic efficacy of antimicrobials: an overview. Transl Neurodegener. 2023;12(1):37

  • Kotey E, Lukosaityte D, Quaye O, Ampofo W, Awandare G, Iqbal M. Current and Novel Approaches in Influenza Management. Vaccines. 2019;7(2):53.

  • Chang P, Sadeyen JR, Bhat S, Daines R, Hussain A, Yilmaz H, et al. Risk assessment of the newly emerged H7N9 avian influenza viruses. Emerg Microbes Infect. 2023;12(1):2172965.

  • Carter T, Iqbal M. The Influenza A Virus Replication Cycle: A Comprehensive Review. Viruses. 2024;16(2):316.

  • Paksu MS, Aslan K, Kendirli T, Akyildiz BN, Yener N, Yildizdas RD, et al. Neuroinfluenza: evaluation of seasonal influenza associated severe neurological complications in children (a multicenter study). Child's Nerv Syst. 2018;34(2):335-347.

  • Froggatt HM, Heaton NS. Nonrespiratory sites of influenza-associated disease: mechanisms and experimental systems for continued study. FEBS J. 2022;289(14):4038-4060.

  • Shafiq I, Wahla AS, Uzbeck MH, Khan N, Zoumot Z. Neuromyelitis Optica Spectrum Disorder Associated with Cryptogenic Organizing Pneumonia in a Young Patient. Eur J Case Rep Intern Med. 2022;9(2):003105.

  • White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, Hartshorn KL. Alzheimer's associated β-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One. 2014;9(7): e101364.

  • Hosseini S, Michaelsen-Preusse K, Schughart K, Korte M. Long-Term Consequence of Non-neurotropic H3N2 Influenza A Virus Infection for the Progression of Alzheimer's Disease Symptoms. Front Cell Neurosci. 2021; 15:643650.

  • Imfeld P, Toovey S, Jick SS, Meier CR. Influenza infections and risk of Alzheimer's disease. Brain Behav Immun. 2016; 57:187–192.

  • Bukhbinder AS, Ling Y, Hasan O, Jiang X, Kim Y, Phelps KN, et al. Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching. J Alzheimer's Dis. 2022;88(3):1061–1074.

  • Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579:265–269.

  • Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020; 395:1137–1144.

  • Tuite AR, Fisman DN, Greer AL. Mathematical modelling of COVID-19 transmission and mitigation strategies in the population of Ontario, Canada. Can Med Assoc J. 2020;192: E497–E505.

  • Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579:270–273.

  • Moazemi-Goudarzi L, Ziafatikafi Z, Seyedasgari F, Najafi H, Hashemzadeh M, Aghaeean L, et al. Molecular Detection of Middle East Respiratory Syndrome Coronavirus from Dromedary Camels Illegally Transferred to Iran. Acta Veter Eurasia. 2022; 48:117–122.

  • Ozer K, Yilmaz A, Carossino M, Ozturk GY, Bamac OE, Tali HE, et al. Clinical, virological, imaging and pathological findings in a SARS-CoV-2 antibody positive cat. J Veter Sci. 2022;23: e52.

  • Yilmaz A, Kayar A, Turan N, Iskefli O, Bayrakal A, Roman-Sosa G, et al. Presence of Antibodies to SARS-CoV-2 in Domestic Cats in Istanbul, Turkey, Before and After COVID-19 Pandemic. Front Vet Sci. 2021; 8:707368.

  • Telenti A, Hodcroft EB, Robertson DL. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12: a041390.

  • Wang Z, Fu Y, Guo Z, Li J, Li J, Cheng H, Lu B, Sun Q. Transmission and prevention of SARS-CoV-2. Biochem Soc Trans. 2020; 48:2307–2316.

  • Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:CD013652.

  • Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.

  • Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690.

  • Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374: n1648.

  • Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593–1607.

  • Amadoro G, Latina V, Stigliano E, Micera A. COVID-19 and Alzheimer's disease share common neurological and ophthalmological manifestations: a bidirectional risk in the post-pandemic future. Cells. 2023;12(22):2601.

  • Ciaccio M, Lo Sasso B, Scazzone C, Gambino CM, Ciaccio AM, Bivona G, et al. COVID-19 and Alzheimer's disease. Brain Sci. 2021;11(3):305.

  • Menekşe Ş, Deniz S. Secondary infections in COVID-19 patients: A two-centre retrospective observational study. J Infect Dev Ctries. 2022;16(8):1294–1301.

  • Lennon JC. What lies ahead: Elevated concerns for the ongoing suicide pandemic. Psychol Trauma. 2020;12(S1): S118–S119.

  • Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, et al. Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post-COVID-19 Conditions. JAMA Psychiatry. 2022;79(11):1081–1091.

  • Baranova A, Cao H, Teng S, Su KP, Zhang F. Shared genetics and causal associations between COVID-19 and multiple sclerosis. J Med Virol. 2023;95(1): e28431.

  • Huang C. Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. Med Virol. 2023;95: e28621. J Med Virol. 2023;95(7): e28907.

  • Vavougios GD, Tseriotis VS, Liampas A, Mavridis T, de Erausquin GA, Hadjigeorgiou G. Type I interferon signaling, cognition and neurodegeneration following COVID-19: update on a mechanistic pathogenetic model with implications for Alzheimer's disease. Front Hum Neurosci. 2024; 18:1352118.

  • Itzhaki RF. Infections, Vaccinations, and Risk of Alzheimer's Disease (AD)/Dementia: Probable Involvement of Reactivated Herpes Simplex Virus Type 1. Adv Exp Med Biol. 2023; 1423:279–280.

  • Bruno F, Abondio P, Bruno R, Ceraudo L, Paparazzo E, Citrigno L, et al. Alzheimer's disease as a viral disease: Revisiting the infectious hypothesis. Ageing Res Rev. 2023; 91:102068.

  • Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670–2702.

  • Duarte LF, Farías MA, Álvarez DM, Bueno SM, Riedel CA, González PA. Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders. Front Cell Neurosci. 2019; 13:46.

  • Carneiro VCS, Alves-Leon SV, Sarmento DJS, Coelho WLDCNP, Moreira ODC, Salvio AL, et al. Herpesvirus and neurological manifestations in patients with severe coronavirus disease. Virol J. 2022;19(1):101.

  • Ashraf GM, Tarasov VV, Makhmutovа A, Chubarev VN, Avila-Rodriguez M, Bachurin SO, Aliev G. The Possibility of an Infectious Etiology of Alzheimer Disease. Mol Neurobiol. 2019;56(6):4479–4491.

  • Bernstein DI. Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review. Antiviral Res. 2020; 180:104821.

  • Rizzo R. Controversial role of herpesviruses in Alzheimer's disease. PLoS Pathog. 2020;16(6): e1008575.

  • James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, Looker KJ. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315–329.

  • Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease? Nat Rev Neurol. 2020;16(4):193–197.

  • Vestin E, Boström G, Olsson J, Elgh F, Lind L, Kilander L, Lövheim H, Weidung B. Herpes Simplex Viral Infection Doubles the Risk of Dementia in a Contemporary Cohort of Older Adults: A Prospective Study. J Alzheimer's Dis. 2024;97(4):1841–1850.

  • Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009;217(1):131–138.

  • Shin E, Chi SA, Chung TY, Kim HJ, Kim K, Lim DH. The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study. Alzheimer's Res Ther. 2024;16(1):57.

  • Tran DN, Bakx ATCM, van Dis V, Aronica E, Verdijk RM, Ouwendijk WJD. No evidence of aberrant amyloid β and phosphorylated tau expression in herpes simplex virus-infected neurons of the trigeminal ganglia and brain. Brain Pathol. 2022;32(4):e13044.

  • Murphy MJ, Fani L, Ikram MK, Ghanbari M, Ikram MA. Herpes simplex virus 1 and the risk of dementia: a population-based study. Sci Rep. 2021;11(1):8691.

  • Vojtechova I, Machacek T, Kristofikova Z, Stuchlik A, Petrasek T. Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity. PLoS Pathog. 2022;18(11): e1010929.

  • Schiffer JT, Mayer BT, Fong Y, Swan DA ,Wald A. Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. J R Soc Interface. 2014;11(95):20140160.

  • Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One. 2015;10(10):e0140765.

  • Berkhout A, Kapoor V, Heney C, Jones CA, Clark JE, Britton PN, et al. Epidemiology and long-term neurological sequelae of childhood herpes simplex CNS infection. J Paediatr Child Health. 2022;58(8):1372–1378.

  • Jakobsen A, Skov MT, Larsen L, Trier Petersen P, Brandt C, Wiese L, et al. Herpes Simplex Virus 2 Meningitis in Adults: A Prospective, Nationwide, Population-Based Cohort Study. Clin Infect Dis. 2022;75(5):753–760.

  • Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015; 1:15016.

  • Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349.

  • Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. 2009;8(8):731–740

  • Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et al.Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA. 2009;106(10):3907–3912.

  • O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98.

  • Tsai MC, Cheng WL, Sheu JJ, Huang CC, Shia BC, Kao LT, Lin HC. Increased risk of dementia following herpes zoster ophthalmicus. PLoS One. 2017;12(11): e0188490.

  • Elhalag RH, Motawea KR, Talat NE, Rouzan SS, Reyad SM, Elsayed SM, et al. Herpes Zoster virus infection and the risk of developing dementia: A systematic review and meta-analysis. Medicine. 2023;102(43): e34503.

  • Ukraintseva S, Akushevich I, Yashkin A, Kravchenko J, Arbeev K, Kulminski A, et al. [P4–347]: on the role of infection in Alzheimer’s disease (AD): herpes viruses are associated with significant increase in AD risk in a large population-representative sample of elderly individuals. Alzheimer's & Dementia. 2017;13: P1423-P1424.

  • Chen VC-H, Wu S-I, Huang K-Y, Yang Y-H, Kuo T-Y, Liang H-Y, Huang K-L, Gossop M. Herpes zoster and dementia: a nationwide population-based cohort study. J Clin Psychiatry. 2018; 79:16m11312.

  • Bae S, Yun SC, Kim MC, Yoon W, Lim JS, Lee SO, Choi SH, Kim YS, Woo JH, Kim SY, Kim SH. Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study. Eur Arch Psychiatry Clin Neurosci. 2021;271(5):987–997.

  • Choi HG, Park BJ, Lim JS, Sim SY, Jung YJ, Lee SW. Herpes zoster does not increase the risk of neurodegenerative dementia: a case-control study. Am J Alzheimers Dis Other Demen. 2021; 36:15333175211006504.

  • Cairns DM, Itzhaki RF, Kaplan DL. Potential involvement of varicella zoster virus in Alzheimer's disease via reactivation of quiescent herpes simplex virus type 1. J Alzheimer's Dis. 2022;88(3):1189–1200.

  • Schmidt SAJ, Veres K, Sørensen HT, Obel N, Henderson VW. Incident herpes zoster and risk of dementia: a population-based Danish cohort study. Neurology. 2022;99(7): e660–e668.

  • Gao J, Feng L, Wu B, Xia W, Xie P, Ma S, et al. The association between varicella zoster virus and dementia: a systematic review and meta-analysis of observational studies. Neurol Sci. 2024;45(1):27–36.

  • Hoover K, Higginbotham K. Epstein-Barr Virus. In StatPearls. StatPearls Publishing, 2023.

  • Estein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1(7335):702–703.

  • Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection. J Clin Virol. 2018; 102:84–92.

  • Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J Glob Health. 2020;10(1):010405.

  • Speck P, Haan KM, Longnecker R. Epstein-Barr virus entry into cells. Virology. 2000;277(1):1–5.

  • Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24(1):193–209.

  • Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008;111(3):1420–1427.

  • Cohen JI, Iwatsuki K, Ko YH, Kimura H, Manoli I, Ohshima K, et al. Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. Leuk Lymphoma. 2020;61(4):808–819.

  • Zhang L, Wang R, Xie Z. The roles of DNA methylation on the promoter of the Epstein-Barr virus (EBV) gene and the genome in patients with EBV-associated diseases. Appl Microbiol Biotechnol. 2022;106(12):4413–4426.

  • Van Gent M, Braem SG, de Jong A, Delagic N, Peeters JG, Boer IG, et al. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling. PLoS Pathog. 2014;10(2):e1003960.

  • Liu X, Cohen JI. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase. J Virol. 2015;90(2):1129–1138.

  • Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, Gabrielli L, Licastro F. Herpes virus in Alzheimer's disease: relation to progression of the disease. Neurobiol Aging. 2014;35(1):122–129.

  • Shim SM, Cheon HS, Jo C, Koh YH, Song J, Jeon JP. Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly. J Alzheimer's Dis. 2017;55(1):293–301

  • Huang YH, Zhang CZ, Huang QS, Yeong J, Wang F, Yang X, He YF, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol. 2021;74(4):838–849.

  • Torniainen-Holm M, Suvisaari J, Lindgren M, Härkänen T, Dickerson F, Yolken RH. Association of cytomegalovirus and Epstein-Barr virus with cognitive functioning and risk of dementia in the general population: 11-year follow-up study. Brain Behav Immun. 2018; 69:480–485.

  • Leonardo S, Fregni F. Association of inflammation and cognition in the elderly: A systematic review and meta-analysis. Front Aging Neurosci. 2023; 15:1069439.

  • Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.

  • Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022;22(1):1659.

  • Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, Waet al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol. 2004;78(20):10960–10966.

  • Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr Opin Infect Dis. 2007;20(4):399–407.

  • Sanami S, Shamsabadi S, Dayhimi A, Pirhayati M, Ahmad S, Pirhayati A, et al. Association between cytomegalovirus infection and neurological disorders: A systematic review. Rev Med Virol. 2024;34(3):e2532.

  • Forte E, Zhang Z, Thorp EB, Hummel M. Cytomegalovirus latency and reactivation: an intricate interplay with the host immune response. Front Cell Infect Microbiol. 2020; 10:130.

  • Ong DSY, Chong GM, Chemaly RF, Cremer OL. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect. 2022;28(10):1335–1344.

  • Barnes LL, Capuano AW, Aiello AE, Turner AD, Yolken RH, Torrey EF, Bennett DA. Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis. 2015;211(2):230–237.

  • Paganelli R, Paganelli A, Pawelec G, Di Iorio A. Natural IgG antibodies to β amyloid are decreased in patients with Parkinson’s disease. Immun Ageing. 2023; 20(1):13.

  • Lurain NS, Hanson BA, Martinson J, Leurgans SE, Landay AL, Bennett DA, Schneider JA. Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis. 2013;208(4):564–572.

  • Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, et al.A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. 2015;22(12):1519–1525.

  • Westman G, Berglund D, Widén J, Ingelsson M, Korsgren O, Lannfelt L, et al. Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer's disease. PLoS One. 2014;9(5): e96779.

  • Lövheim H, Olsson J, Weidung B, Johansson A, Eriksson S, Hallmans G, Elgh F. Interaction between cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer's disease development. J Alzheimer's Dis. 2018;61(3):939–945.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!